PSA在前列腺增生和前列腺癌中的诊断价值

目的：探讨临床上检测前列腺特异性抗原（PSA）的变化情况对前列腺增生和前列腺癌等疾病的诊断价值。方法：采用回顾性分析的方法，选取2010年6月至2012年4月在我院泌尿科接受治疗的前列腺增生患者64例定义为前列腺增生组（BPH），前列腺癌患者83例定义为前列腺癌组（PCa），另选取同期接受体检的健康人群137例作为对照组。分别检测三组患者入院时的游离前列腺特异性抗原和总前列腺特异性抗原的水平变化情况。对比并分析三组检测结果。结果：经检测，前列腺增生患者的血清总PSA明显高于对照组健康人群的正常值，而前列腺癌患者的血清总PSA比前列腺增生患者增高的更为明显。对照组游离PSA为（2．78±0．94）ng／mL，总PSA（1．05±0．57）ng／mL，游离PSA与总PSA的比值为，（0．38±0．61）；前列腺增生患者游离PSA为（6．36＋3．24）ng／mL，总PSA为（1．64±0．76）ng／mL，游离PSA与总PSA的比值为（0．26±0．23）；前列腺癌患者游离PSA为（12．42±4．97）ng／mL，总PSA为（1．44±0．78）ng／mL，游离PSA与总PSA的比值为（0．12±0．16）。组间比较差异明显，具有统计学意义（P〈0．05）。结论：对患者的PSA进行检测，对前列腺增生和前列腺癌的诊断具有良好的辅助作用和，临床价值。

Diagnostic Value of PSA on Prostate Hyperplasia and Prostate Cancer

Objective： To investigate the diagnostic values of detecting the Prostate Specific Antigen（PSA） changes on the prostate hyperplasia and prostate cancer. Methods： A retrospective case analysis was performed on this investigation. 64 patients with benign pro- static hyperplasia who were treated in our hospital from June 2010 to April 2012 were selected to be the BPH group, 83 patients with prostate cancer were defined as the PCa group, and another 137 healthy people who were taken the physical examination at the same time were chosen as the control group. Then the free PSA, total PSA and the ratio of them in the three groups were detected respectively. The detection results were compared and analyzed. Results： By means of the detection, the total PSA in serum of the patients in BPH group was significantly higher than that of the control group＇s, while the total PSA in serum of the patients in PCa group was further higher than that of the control group＇s. In the control group, f-PSA was（2.78± 0.94） ng/mL, t-PSA was （1.05±0.57） ng/mL, and f/t PSA was （0.38± 0.61）; in BPH group, f-PSA was （6.36± 3.24） ng/mL, t-PSA was （1.44 ± 0.78） ng/mL, and f/t PSA was （0.26± 0.23）; in PCa group, f-PSA was （12.42± 4.97） ng/mL, t-PSA was （1.44 ± 0.78） ng/mL, and f/t PSA was （0.12 ± 0.16）. There were statistically significant differences among three groups about the results of detecting the PSA in serum （P〈0.05）. Conclusion： It is suggested that the detection of PSA could make contribution to the diagnosis and clinical significance of prostatic hyperplasia and prostate cancer.